Abstract
Hepatitis B surface antigen (HBsAg) loss is considered a functional cure in chronic hepatitis B (CHB). However, the durability of HBsAg loss after stopping treatment remains unknown. This study aimed to assess the sustained functional cure achieved by interferon therapy in hepatitis B envelope antigen (HBeAg)-negative CHB patients. In this prospective study, 176HBeAg-negative CHB patients with functional cure were enrolled for 12weeks of cessation treatment, and treatment information and baseline data were collected. Hepatitis B virus (HBV) biomarkers and clinical biochemical indicators were evaluated every 3months; liver imaging examinations were performed every 3-6months during the 48-week follow-up. The sustained functional cure was evaluated. After the 48-week follow-up, the sustained functional cure rate was 86.63%. The cumulative rates of HBsAg reversion and HBV DNA reversion were 12.79% and 2.33%, respectively. Consolidation treatment≥12weeks after HBsAg loss achieved a significantly higher rate of sustained functional cure and significantly lower rate of HBsAg reversion than consolidation treatment<12weeks (76.19% vs 90.00%, P=0.022 and 23.81% vs 9.23%, P=0.014, respectively). Patients with hepatitis B surface antibody (HBsAb) had higher rate of sustained functional cure than patients achieving HBsAg loss but without HBsAb (89.86% vs 73.53%, P=0.012). Consolidation treatment≥12weeks (odds ratio [OR] 16.478; 95% confidence interval [CI], 2.135-127.151; P=0.007) and high HBsAb levels (OR 8.312; 95% CI, 1.824-37.881; P=0.006) were independent predictors of sustained functional cure. Results suggested that 12weeks of consolidation therapy after HBsAg clearance and elevated HBsAb levels help to improve functional cure.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have